Multi-drug approaches to NASH: what’s in the development pipeline?-Reference-Cited by-同舟云学术

Multi-drug approaches to NASH: what’s in the development pipeline?

Published:2019-09-23 Issue:2 Volume:29 Page:143-150
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Johnston Michael P¹^ORCID,Patel Janisha¹,Byrne Christopher D²³

Affiliation:

1. Department of Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

2. Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK

3. National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, UK

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1668926

Reference34 articles.

1. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

2. NAFLD: A multisystem disease

3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

4. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the therapeutic efficacy of FGF19 and FGF21 in NAFLD: A comparative genomic and metabolic analysis;Food Bioscience;2024-08

2. A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials;Journal of Endocrinological Investigation;2023-10-15

3. Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations;PLOS ONE;2023-03-31

4. CDCDB: A large and continuously updated drug combination database;Scientific Data;2022-06-02

5. Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome;Frontiers in Pharmacology;2022-05-02